As of June 18, 2025, Qualigen Therapeutics Inc (QLGN) reports a EV/EBITDA of -0.20.
EV/EBITDA evaluates a company's total value relative to its earnings before interest, taxes, depreciation, and amortization, useful for comparing firms with different capital structures.
Comparing Qualigen Therapeutics Inc's EV/EBITDA to Peers
To better understand Qualigen Therapeutics Inc's position, it's useful to compare its EV/EBITDA against industry peers. Below are selected comparisons:
| Company | EV/EBITDA |
|---|---|
| Qualigen Therapeutics Inc (QLGN) | -0.20 |
| Abbvie Inc (ABBV) | 17.90 |
| Amgen Inc (AMGN) | 15.21 |
| Regeneron Pharmaceuticals Inc (REGN) | 12.54 |
| Gilead Sciences Inc (GILD) | 9.30 |
| Aprea Therapeutics Inc (APRE) | 0.62 |
Compared to its competitors, Qualigen Therapeutics Inc's EV/EBITDA is about average compared to peers, indicating market valuation in line with industry expectations.